Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementation

Background: Awareness about the importance of implementing DPYD pharmacogenetics in clinical practice to prevent severe side effects related to the use of fluoropyrimidines has been raised over the years. Since 2012 at the National Cancer Institute, CRO-Aviano (Italy), a diagnostic DPYD genotyping s...

Descripción completa

Detalles Bibliográficos
Autores principales: Bignucolo, A., De Mattia, E., Roncato, R., Peruzzi, E., Scarabel, L., D’Andrea, M., Sartor, F., Toffoli, G., Cecchin, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225682/
https://www.ncbi.nlm.nih.gov/pubmed/37256229
http://dx.doi.org/10.3389/fphar.2023.1199462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225682/
https://www.ncbi.nlm.nih.gov/pubmed/37256229
http://dx.doi.org/10.3389/fphar.2023.1199462

Ejemplares similares